Recent data suggests that initiation of ART early in infection confers several benefits on HIV-related morbidity and clinical outcomes. Because initiation of ART during acute infection is not currently a viable public health strategy, it is important to investigate the relative long-term benefits of starting ART at different times during early infection. We evaluated how timing of ART initiation impacts the gastrointestinal microbiome during early infection in a subset of the Sabes study, a randomized clinical trial in Peru.
HIV-infected MSM and transgender women who were diagnosed while sero-negative (acute HIV, A), or were sero-positive and 90 days or less from last negative RNA test (recent HIV, R) were randomized within strata to receive standard-of care ART immediately (I) or after 24 weeks deferral (D). Cryopreserved stool samples collected from enrollment to 24 wks, including 1, 2, 4,8 and 16 wks, were analyzed in 29 participants who started ART in acute infection (AI, N=8), recent infection (RI, N=12), or after 24 weeks deferral (AD, N=4; RD, N=5). The V4 hypervariable region of the 16S rRNA gene was sequenced on the Illumina Nextseq and the resulting microbiota profiles were analyzed. Differences in bacterial community composition were assessed both longitudinally and cross-sectionally using weighted UniFrac; statistical significance was determined using Linear Mixed Effects Models (LME) and permutational multivariate ANOVA (PERMANOVA), respectively.
Using repeated measure analyses, significant differences in the bacterial community composition (beta diversity scores) were observed in the AD group compared to either of recent infection groups (LME, p=0.009 and 0.007 for the RI and RD groups, respectively). Significant differences in bacterial community composition based on a 4-way comparison (groups AI, AD, RI, RD) were also observed at the 1 (p=0.035), 2 (p=0.007) and 24 (p=0.025) week collections with trends toward significant differences at enrollment (p=0.142) and the 4 (p=0.133) week collection.
Our pilot data indicate that time of ART initiation after HIV acquisition is associated with significant differences in gut microbiota composition of HIV-infected patients. Microbiome analysis of samples from HIV uninfected and chronically infected controls, as well as analysis of the microbiome, latent HIV reservoir, and immunologic function in this cohort during long-term follow-up (up to 4.5 years after diagnosis) is ongoing in the MERLIN study.